Search Results for: Other News to Note
-
Other News To Note
The agreement and manufactured drug will be used to complete the investigational new drug application for pivotal trials of Zertane in the U.S., complete the registration package for approval of Zertane in Australia based on completed Phase III European trials and finalize pricing of the drug for launch in other countries and for licensing negotiations with additional potential partners...The contract also provides for CSL to develop virus seeds for other manufacturers...Sucampo Pharmaceuticals Inc -
Other News To Note
CTI plans to expand to other European countries next year...OncoSec Medical Inc., of San Diego, secured an exclusive license for patented technology from the University of South Florida Research Foundation related to the delivery of gene-based therapeutics through intratumoral and intramuscular electroporation -
Pharma: Other News To Note
to collaborate on a Phase III trial testing ASP0113 (TransVax), an investigational vaccine licensed from Vical Inc., of San Diego, for preventing cytomegalovirus (CMV) reactivations in transplant patients -
Other News To Note
government will pay up to 50 percent of the cost of Voraxaze to hospitals in addition to the standard diagnosis-related group (DRG) reimbursement payment -
Other News To Note
BioLineRx plans to begin a Phase II trial of BL-8040 in the first half of 2013 in acute myeloid leukemia...Cellceutix plans to begin the trials once the study supplies are produced...To-BBB Technologies BV, of Leiden, the Netherlands, received €1.25 million (US$1.57 million) for development of new therapies for inherited retinal degenerative diseases -
Other News To Note
Cadence Pharmaceuticals Inc., of San Diego, and SCR Pharmatop SA, of France, said they received a Markman claim construction ruling in district court in their ongoing patent infringement case against Paddock Laboratories Inc., Perrigo Co., Paddock Laboratories LLC, Exela Pharma Sciences LLC, Exela Pharmsci Inc...The letter is in response to opposition from one of Nabi's largest stockholders, Mangrove Partners Fund LP, which last week reached out to shareholders asking them to vote against the -
Other News To Note
CRT said that CTx-0294886 could be used to treat other cancers, including a subset of acute myeloid leukemia (AML) patients with mutations in FLT3, a receptor tyrosine kinase involved in controlling the growth and development of several blood cancers, including AML...Santarus Inc., of San Diego, said the FDA has extended the PDUFA date for its ulcerative colitis drug Uceris (budesonide) tablets 9 mg to Jan. 16, 2013 -
Other News To Note
MEI Pharma Inc., of San Diego, will acquire Singapore-based S*BIO Pte Ltd.'s exclusive worldwide rights to pracinostat, an oral histone deacetylase inhibitor of interest for hematologic diseases and solid tumors...Rosetta plans to use the proceeds to fund its general corporate operations...Sun Pharmaceutical Industries Ltd., of Mumbai, India, will acquire Taro Pharmaceutical Industries Ltd., of Hawthorne, N.Y., for $39.50 in cash per share paid to shareholders other than Sun Pharma and its affiliates -
Other News To Note
Investors shrugged at the news, with the company's shares (NASDAQ:AMGN) gaining 60 cents in light trading, closing at $81.97...BMS exercised its right to purchase additional shares from Amylin, allowing the pharma to complete the merger without stockholder approval -
Pharma: Other News To Note
BMS exercised its right under the merger agreement to purchase additional Amylin shares at $31 each so it can complete the acquisition...The approval will allow the company to continue operations and focus on restructuring its financial obligations. (See BioWorld Today, Aug. 7, 2012...Pfizer Inc., of New York, licensed the exclusive rights to Pittsburg-based Mylan Inc.'s next-generation EpiPen Injection 0.3/0.15 mg in Japan -
Other News To Note
MEI Pharma Inc., of San Diego, will acquire Singapore-based S*BIO Pte Ltd.'s exclusive worldwide rights to pracinostat, an oral histone deacetylase inhibitor of interest for hematologic diseases and solid tumors...in order to respond to growing demand from clinical trial sites for its Phase III trial in glioblastoma -
Other News To Note
In lieu of the additional confirmatory Phase III study it had called for in the CRL, the agency agreed to accept further analyses of the data from the AMP-516 Phase III trial and other Ampligen trials...Zogenix Inc., of San Diego, said it used some of the proceeds from last month's $60.7 million offering to pay off its $19.5 million outstanding loan agreement with Oxford Finance LLC and Silicon Valley Bank...In addition to a $400,000 prepayment premium on the loan, Zogenix paid a $100,000 prepayment -
Other News To Note
Ltd., of Tokyo, to use Anchor's pepducin technology to advance Kyowa's internal G protein-coupled receptor (GPCR) drug discovery portfolio...OrPro Therapeutics Inc., of San Diego, received a National Heart, Lung and Blood Institute Small Business Innovation Research grant from the National Institutes of Health to advance development of its lead product, ORP-100, in cystic fibrosis -
Other News To Note
Arena Pharmaceuticals Inc., of San Diego, transferred the Belviq (lorcaserin hydrochloride) new drug application to partner Eisai Inc., of Woodcliff Lake, N.J., which establishes Eisai as the marketing authorization holder responsible for regulatory activities in the U.S...related to commercialization of the obesity drug, including pharmacovigilance requirements...Cabozantinib is designed to inhibit MET, VEGFR2 and RET -
Other News To Note
Cardium Therapeutics Inc., of San Diego, published preclinical findings demonstrating that cardiac ischemia plays an important role in adenovector gene delivery in mammalian hearts...The company said it understands that those data led to the EMA's July 19 recommendation suggesting evidence of a small increased risk of cancer with long-term use of certain calcitonin medications available in Europe and calling for a curtailment in the usage of those products -
Other News To Note
Ligand Pharmaceuticals Inc., of San Diego, reported that the FDA granted priority review to its partner GlaxoSmithKline plc, of London, for the supplemental new drug application for Promacta (eltrombopag) to treat thrombocytopenia in adult patients with chronic hepatitis C. Promacta, marketed as Revolade outside the U.S., is approved in 89 countries to treat chronic immune thrombocytopenia. (See BioWorld Today, Nov. 24, 2008 -
Other News To Note
Catalent Inc., of San Diego, began supplying Abilify OD Tablets (orally disintegrating tablets) using its Zydis fast-dissolve drug delivery technology to Otsuka Pharmaceutical Co...In other news from Forest, shareholder Carl Icahn and the company are continuing their battle over the leadership and direction of the firm in advance of an Aug. 15 annual meeting -
Other News To Note
The change follows Shire's announcement that it planned to build a regenerative medicine campus in San Diego to expand its operational footprint and presence in the area over the next several years -
Pharma: Other News To Note
The change follows Shire's announcement that it planned to build a regenerative medicine campus in San Diego to expand its operational footprint and presence in the area over the next several years. (See BioWorld Today, June 12, 2012 -
Other News To Note
According to the EMA timetable, Alexza expects to receive the Day 180 list of outstanding issues in late September...to mucoadhesive product Oravig (known as Loramyc in Europe) for the treatment of oropharyngeal candidiasis in adults
Category
Current Filters
- xSan Diego
Related Keywords
Categories
- x BioWorld Today (2868)
- x BioWorld International (181)
- x BioWorld Insight (16)
- x Bio Perspectives (10)